Skip to main content

Annexon, Inc.

corporate_fare Company Profile

Annexon, Inc.

ANNX·NASDAQ·Life Sciences·CIK 0001528115

Annexon, Inc. is a biopharmaceutical company that develops targeted immunotherapies for complement-mediated neuroinflammatory diseases. These diseases affect nearly 10 million people globally. The company focuses on the classical complement pathway, a part of the body's immune system that triggers inflammation. Annexon aims to stop this pathway at its beginning by targeting C1q, its initiating molecule. This approach is intended to offer comprehensive protection against complement-mediated disorders affecting the body, brain, and eye. Using its proprietary platform, Annexon identifies and characterizes the classical complement pathway's role in three therapeutic areas: autoimmune diseases, neurodegeneration, and ophthalmology. The company is developing product candidates designed to block the early classical cascade and all subsequent pathway components and their tissue-damaging effects. The objective is to suppress excessive or abnormal classical complement activity that causes chronic inflammation and tissue damage, potentially slowing or halting disease progression. This is done while preserving the beneficial immune functions of the lectin and alternative complement pathways, which are involved in clearing pathogens and damaged cells. With over a decade of experience in addressing neuroinflammation, Annexon has shown strong target engagement in the body, brain, and eye, and has achieved clinical proof of concept in multiple diseases.

Annexon, Inc. (NASDAQ:ANNX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 22 items for ANNX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-09, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 7 rated 8 or above. Recent SEC coverage for ANNX spans 8-K, 10-Q, 4, PRE 14A.

Recent high-impact activity:

  • Annexon Posts Q3 Loss of $0.25/Share, $213M Cash, Adds $200M Oxford Credit Facility
  • Annexon Posts $51.2M Q3 Loss, Adds $200M Oxford Credit Facility Ahead of Q4 BLA Filing
  • Annexon Q2 2026: $55.3M Net Loss, Cash Runway Extended into 2028
  • Annexon Posts Q2 Loss of $0.28/Share, Expands Phase 3 GA Trial with Dual Endpoint, and Sets Key Milestones
  • Annexon Posts 28c Q2 Loss, Cash Runway in Focus

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$206.69M
Diluted EPS
-$1.34
Op. Cash Flow
-$186.36M
Free Cash Flow
-$186.49M
Operating Income
-$216.41M
Cash & Equivalents
$162.05M
Debt / Equity
0.00×
Shares Outstanding
149.36M sh
Source: 10-K · filed 2026-03-30 · accession 0001193125-26-131782

Short Interest & Short Volume

7.19 days to cover

FINRA reported short interest of 28,984,850 shares in ANNX as of the October 30, 2026 settlement, a 8.4% decrease from the prior period — about 7.2 days to cover at its recent average daily volume. On November 20, 2026, 36.5% of ANNX volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)28,984,850 shares as of October 30, 2026
Change vs prior period▼ 8.4%
Days to cover7.19 at avg daily volume of 4,030,996
Daily short volume (FINRA facilities)36.5% of 1,922,133 shares on November 20, 2026
5-day average short volume40.4%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Low risk

Filing-implied dilution signals for ANNX, detected from its recent SEC filings · based on capital-structure filings through 2026-06-12.

Authorized Shares Increased · Significant Potential Dilution

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with A →
$3.41 +10.00% today
52-week range · as of 2026-11-09 $2.54 – $7.18
Market cap
$591.37M
Volume
4.5M (1.2× avg)
3-mo avg 3.6M
Live data · 2026-11-21 13:51 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed ANNX - Latest Insights

ANNX
Nov 09, 2026, 4:05 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $4.23
Real-time Price: $3.41 info
Change: -$0.820 (-19%) info
Market Cap: $591.368M info
ANNX
Nov 09, 2026, 4:01 PM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $4.23
Real-time Price: $3.41 info
Change: -$0.820 (-19%) info
Market Cap: $591.368M info
ANNX
Aug 12, 2026, 4:00 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $5.35
Real-time Price: $3.41 info
Change: -$1.94 (-36%) info
Market Cap: $591.368M info
ANNX
Aug 12, 2026, 6:30 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $5.01
Real-time Price: $3.41 info
Change: -$1.60 (-32%) info
Market Cap: $591.368M info
ANNX
Aug 12, 2026, 6:05 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $5.46
Real-time Price: $3.41 info
Change: -$2.05 (-38%) info
Market Cap: $591.368M info
ANNX
Aug 12, 2026, 6:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $5.21
Real-time Price: $3.41 info
Change: -$1.80 (-35%) info
Market Cap: $591.368M info
ANNX
Aug 06, 2026, 8:17 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $5.44
Real-time Price: $3.41 info
Change: -$2.03 (-37%) info
Market Cap: $591.368M info
ANNX
Jul 30, 2026, 4:25 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $5.37
Real-time Price: $3.41 info
Change: -$1.96 (-36%) info
Market Cap: $591.368M info
ANNX
Jul 20, 2026, 7:21 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $5.86
Real-time Price: $3.41 info
Change: -$2.45 (-42%) info
Market Cap: $591.368M info
ANNX
Jul 14, 2026, 4:05 PM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $5.46
Real-time Price: $3.41 info
Change: -$2.05 (-38%) info
Market Cap: $591.368M info
ANNX
Jun 12, 2026, 4:16 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $4.62
Real-time Price: $3.41 info
Change: -$1.21 (-26%) info
Market Cap: $591.368M info
ANNX
May 29, 2026, 5:21 PM EDT
Filing Type: 4
Importance Score:
7
Price at Filing: $5.70
Real-time Price: $3.41 info
Change: -$2.29 (-40%) info
Market Cap: $591.368M info
ANNX
May 07, 2026, 4:12 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $5.65
Real-time Price: $3.41 info
Change: -$2.24 (-40%) info
Market Cap: $591.368M info
ANNX
May 07, 2026, 4:01 PM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $5.52
Real-time Price: $3.41 info
Change: -$2.11 (-38%) info
Market Cap: $591.368M info
ANNX
Apr 16, 2026, 4:06 PM EDT
Filing Type: PRE 14A
Importance Score:
9
Price at Filing: $6.33
Real-time Price: $3.41 info
Change: -$2.92 (-46%) info
Market Cap: $591.368M info
ANNX
Mar 30, 2026, 7:42 PM EDT
Filing Type: S-3ASR
Importance Score:
7
Price at Filing: $4.96
Real-time Price: $3.41 info
Change: -$1.55 (-31%) info
Market Cap: $591.368M info
ANNX
Mar 30, 2026, 5:30 PM EDT
Filing Type: 10-K
Importance Score:
7
Price at Filing: $4.95
Real-time Price: $3.41 info
Change: -$1.54 (-31%) info
Market Cap: $591.368M info
ANNX
Mar 30, 2026, 5:29 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $4.95
Real-time Price: $3.41 info
Change: -$1.54 (-31%) info
Market Cap: $591.368M info
ANNX
Mar 30, 2026, 4:01 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $4.95
Real-time Price: $3.41 info
Change: -$1.54 (-31%) info
Market Cap: $591.368M info
ANNX
Mar 30, 2026, 4:01 PM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $4.96
Real-time Price: $3.41 info
Change: -$1.55 (-31%) info
Market Cap: $591.368M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets